Inhibrx Biosciences reported net income of -$36.65M for the quarter ended Jun 2026. This income statement covers 12 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 10.91M | 11.79M | 11.78M | 13.64M | 14.48M | 14.48M | 14.48M | 14.48M | 14.48M | 14.50M | 14.58M | 14.71M |
| Revenue & cost | ||||||||||||
| Revenue | 0.03M | 0.12M | 1.63M | 0.10M | 0.10M | 1.30M | ||||||
| Operating items | ||||||||||||
| Research & DevelopmentR&D | 34.11M | 38.06M | 82.09M | 63.85M | 67.63M | 38.89M | 33.37M | 36.88M | 22.27M | 28.54M | 25.35M | 23.90M |
| Selling, General & AdministrativeSG&A | 7.26M | 7.89M | 7.83M | 9.97M | 93.37M | 7.90M | 16.66M | 6.02M | 6.42M | 5.28M | 5.57M | 8.25M |
| Operating ExpensesOpex | 41.37M | 45.95M | 89.92M | 73.83M | 161.00M | 46.80M | 50.03M | 42.90M | 28.69M | 33.81M | 30.92M | 32.15M |
| Operating IncomeOp. Inc | -41.34M | -45.83M | -88.29M | -73.83M | -160.90M | -46.80M | -49.93M | -42.90M | -27.39M | -33.81M | -30.92M | -32.15M |
| EBIT | -41.34M | -45.83M | -88.29M | -73.83M | -160.90M | -46.80M | -49.93M | -42.90M | -27.39M | -33.81M | -30.92M | -32.15M |
| Non-operating items | ||||||||||||
| Non Operating Interest Expenses | 7.91M | 8.15M | 8.22M | 8.13M | 5.36M | 2.69M | 3.14M | 3.18M | 3.19M | 5.69M | ||
| Interest & Investment IncomeInt & Inv Inc | 2.41M | 2.32M | 4.70M | 3.30M | 2.74M | 2.89M | 2.00M | 2.33M | 2.12M | 1.78M | 1.31M | 1.26M |
| Other Non Operating IncomeOther Non Op Inc. | -0.22M | -0.14M | -0.16M | -0.06M | 0.03M | 0.04M | 0.06M | -0.05M | -0.25M | -0.05M | -0.04M | -0.07M |
| Non Operating IncomeNon Op. Inc. | -5.71M | -5.96M | -3.69M | -4.88M | 2,018.91M | 2.93M | 2.06M | -0.41M | -1.26M | -1.44M | -1.91M | -4.50M |
| Net income details | ||||||||||||
| EBT | -47.05M | -51.79M | -91.97M | -78.71M | 1,858.01M | -43.86M | -47.87M | -43.31M | -28.65M | -35.26M | -32.83M | -36.65M |
| Tax ProvisionsTaxes | 0.01M | 0.00M | -0.00M | 0.00M | 0.00M | 0.00M | ||||||
| Profit After TaxPAT | -47.05M | -51.79M | -93.60M | -78.71M | 1,858.01M | -43.86M | -47.87M | -43.31M | -28.65M | -35.26M | -32.83M | -36.65M |
| Income from Continuing OperationsIncome (Continuing) | -47.05M | -51.79M | -91.97M | -78.71M | 1,858.01M | -43.86M | -47.87M | -43.31M | -28.65M | -35.26M | -32.83M | -36.65M |
| Consolidated Net IncomeConsol Net Inc. | -47.05M | -51.79M | -91.97M | -78.71M | 1,858.01M | -43.86M | -47.87M | -43.31M | -28.65M | -35.26M | -32.83M | -36.65M |
| Income towards Parent CompanyParent Net Inc | -47.05M | -51.79M | -91.97M | -78.71M | 1,858.01M | -43.86M | -47.87M | -43.31M | -28.65M | -35.26M | -32.83M | -36.65M |
| Net Income towards Common StockholdersNet Income | -47.05M | -51.79M | -91.97M | -78.71M | 1,858.01M | -43.86M | -47.87M | -43.31M | -28.65M | -35.26M | -32.83M | -36.65M |
| Additional items | ||||||||||||
| EPS (Basic) | -4.31 | -4.39 | -7.81 | -5.77 | 127.10 | -2.84 | -3.23 | -2.80 | -1.85 | -2.28 | -2.12 | -2.34 |
| EPS (Diluted) | -4.31 | -4.39 | -7.81 | -5.77 | 125.48 | -2.84 | -3.19 | -2.80 | -1.85 | -2.28 | -2.12 | -2.34 |
| Shares Outstanding | 10.91M | 11.79M | 11.78M | 13.64M | 14.62M | 15.47M | 14.80M | 15.47M | 15.47M | 15.48M | 15.49M | 15.67M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 10.91M | 11.79M | 11.78M | 13.64M | 14.81M | 15.47M | 14.98M | 15.47M | 15.47M | 15.48M | 15.49M | 15.67M |
| EBITDA | -41.34M | -45.83M | -88.29M | -73.83M | -160.90M | -46.80M | -49.93M | -42.90M | -27.39M | -33.81M | -30.92M | -32.15M |
| Interest ExpensesInt Expense | 7.91M | 8.15M | 8.22M | 8.13M | 5.36M | 2.69M | 3.14M | 3.18M | 3.19M | 5.69M | ||
| Tax Rate | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |